More Changes In Carcinogenesis Program At NCI: Gori, Workshops Out, Branch Chiefs Running It
In Brief: NCI Can Proceed With Grant, Contract Awards At Full FY 1978 Level; Rundles Heads ACS
Board Defers core Guideline changes, Asks Subcommittee For Alternate Plans
First analysis From Profiles Reveal New Data On Centers
New research Suggested For Immunobiology
NCI Offers Chlorozotocin
To Industry for Development, NDA
Drug Development Gets Extra $500,000
Trending Stories
- Federal judge blocks Trump administration’s move to limit indirect costs to 15% for NIH-funded institutions
The move could gut academic cancer research - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - “Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender
Medical group sues over removing “information used every day by health professions” - Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills